Pazopanib-Induced Asymptomatic Necrotizing Pancreatitis Diagnosed on 18F-FDG PET-CT Scan

Multi-targeted tyrosine kinase inhibitor (TKI) pazopanib approved for the treatment of advanced soft tissue sarcoma (STS) has prolonged the estimated survival times and quality of life of patients. However, several adverse effects associated predominantly with the inhibition of the vascular endothelial growth factor receptor by these drugs may prove to be potentially life-threatening. One such rare adverse event with the use of pazopanib is acute pancreatitis. We present a case of asymptomatic necrotizing pancreatitis induced by pazopanib treatment for metastatic STS detected on 18F-FDG PET-CT imaging.

[1]  A. Agrawal,et al.  Regorafenib-Associated Acute Pancreatitis Diagnosed on 18F-FDG PET/CT. , 2020, Clinical nuclear medicine.

[2]  R. Desikan,et al.  Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response , 2020, EJHaem.

[3]  C. Rolfo,et al.  Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report , 2017, Molecular and clinical oncology.

[4]  G. Murtaza,et al.  Acute Pancreatitis Related to a Chemotherapy Drug , 2017, World journal of oncology.

[5]  Robin L. Jones,et al.  Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin , 2016, Cancer management and research.

[6]  B. Vincenzi,et al.  Pazopanib and pancreatic toxicity: a case report , 2015, BMC Research Notes.

[7]  G. Naik,et al.  Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. , 2014, Critical reviews in oncology/hematology.

[8]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[9]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[10]  J. Mayerle,et al.  Drug-Induced Pancreatitis , 2012, Current Gastroenterology Reports.

[11]  Patrick Schöffski,et al.  Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.